Alnylam Pharmaceuticals (ALNY) Revenue Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Revenue Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 9.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 10.18% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 12.45% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 16.73% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 59.71% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 2.11% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 66.86% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 3.42% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 296.11% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -58.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.86% |
| Mar 31, 2026 | 3,790.58% |
| Dec 31, 2025 | 84.95% |
| Sep 30, 2025 | 149.35% |
| Jun 30, 2025 | 17.26% |
| Mar 31, 2025 | -93.93% |
| Dec 31, 2024 | 34.90% |
| Sep 30, 2024 | -33.26% |
| Jun 30, 2024 | 107.00% |
| Mar 31, 2024 | 54.82% |
| Dec 31, 2023 | 31.25% |
| Sep 30, 2023 | 183.96% |
| Jun 30, 2023 | 41.78% |
| Mar 31, 2023 | 49.72% |
| Dec 31, 2022 | 29.59% |
| Sep 30, 2022 | 40.86% |
| Jun 30, 2022 | 1.93% |
| Mar 31, 2022 | 20.10% |
| Dec 31, 2021 | 58.07% |
| Sep 30, 2021 | 49.09% |